Paul Engstrom, MD
Ophthalmology · Roswell, NMNPI 1003884602
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 37.4% of the total. Reporting peaked in 2019 at $205 and has fallen 59.5% since, to $83 in 2025. That places this record below the midpoint for ophthalmology clinicians in NM, where the typical reported total is $868.
Across 25 payments — averaging $26.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$250
- Bausch & Lomb Americas Inc.$122
- Ivantis, Inc$74
- Carl Zeiss Meditec, Inc.$54
- Alcon$45
- Glaukos Corporation$34
- plus $90 from 4 others
What the payments were for
- Food & beverage$669100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 7 | $250 |
| Bausch & Lomb Americas Inc. | 5 | $122 |
| Ivantis, Inc | 3 | $74 |
| Carl Zeiss Meditec, Inc. | 2 | $54 |
| Alcon | 1 | $45 |
| Glaukos Corporation | 2 | $34 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $31 |
| Amgen | 2 | $26 |
| Astellas Pharma US Inc | 1 | $17 |
| Sight Sciences, Inc. | 1 | $16 |
How this compares
$669 in reported general payments places this provider in the 40th percentile of 81 ophthalmology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Latanoprost | 436 | $6,221 |
| Travoprost | 23 | $5,763 |
| Brimonidine Tartrate | 157 | $4,437 |
| Timolol Maleate | 297 | $4,126 |
| Timolol MaleateTimolol Maleate/Pf | 11 | $3,551 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $3,446 |
| Prednisolone Acetate | 34 | $1,982 |
| Ketorolac Tromethamine | 75 | $1,608 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 62 | $1,110 |
| Dorzolamide Hcl | 63 | $864 |
| Ofloxacin | 13 | $176 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Roswell
- Grace MellgrenRoswell$2K
- Mark GallardoLas Cruces$1.2M
- Robert MelendezAlbuquerque$349K
- John PitcherAlbuquerque$307K
- Christopher RoybalAlbuquerque$51K
- Paul GulbasRuidoso$14K
- Stephen ColemanAlbuquerque$12K
- Rachel DavisAlbuquerque$10K
- Ian ThompsonAlbuquerque$10K
- Paul SanchezAlbuquerque$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.